Filing Details

Accession Number:
0001104659-23-022917
Form Type:
13G Filing
Publication Date:
2023-02-16 19:00:00
Filed By:
Cedars Sinai Intellectual Property Co
Company:
Prometheus Biosciences Inc.
Filing Date:
2023-02-17
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Cedars Sinai Intellectual Property Company 0 4,866,132 0 4,866,132 4,866,132 10.5%
Filing

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 1) *

 

Prometheus Biosciences, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

 

74349U 108
(CUSIP Number)

 

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)
   
¨Rule 13d-1(c)
   
xRule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP NO. 74349U 108    

 

1 NAMES OF REPORTING PERSONS
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
   
  Cedars Sinai Intellectual Property Company
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
  (a) ¨
   (b) x
3 SEC USE ONLY
   
4 CITIZENSHIP OR PLACE OF ORGANIZATION
   
  California
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5 SOLE VOTING POWER
   
  0
6 SHARED VOTING POWER
   
  4,866,132
7 SOLE DISPOSITIVE POWER
   
  0
8 SHARED DISPOSITIVE POWER
   
  4,866,132
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  4,866,132 shares
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)                   ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
  10.5%
12 TYPE OF REPORTING PERSON (See Instructions)
  CO

 

 

 

 

CUSIP NO. 74349U 108    

 

1 NAMES OF REPORTING PERSONS
   
  Cedars-Sinai Medical Center
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
  (a) ¨
   (b) x
3 SEC USE ONLY
   
4 CITIZENSHIP OR PLACE OF ORGANIZATION
   
  California
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5 SOLE VOTING POWER
   
  0
6 SHARED VOTING POWER
   
  4,866,132
7 SOLE DISPOSITIVE POWER
   
  0
8 SHARED DISPOSITIVE POWER
   
  4,866,132
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  4,866,132
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)                   ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
  10.5%
12 TYPE OF REPORTING PERSON (See Instructions)
  CO

 

 

 

 

CUSIP NO. 74349U 108    

 

1 NAMES OF REPORTING PERSONS
   
  Thomas M. Priselac
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
  (a) ¨
   (b) x
3 SEC USE ONLY
   
4 CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5 SOLE VOTING POWER
   
  0
6 SHARED VOTING POWER
   
  4,866,132
7 SOLE DISPOSITIVE POWER
   
  0
8 SHARED DISPOSITIVE POWER
   
  4,866,132
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  4,866,132
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)                   ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
  10.5%
12 TYPE OF REPORTING PERSON (See Instructions)
  IN

 

 

 

 

CUSIP NO. 74349U 108    

 

1 NAMES OF REPORTING PERSONS
   
  David M. Wrigley
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
  (a) ¨
   (b) x
3 SEC USE ONLY
   
4 CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5 SOLE VOTING POWER
   
  0
6 SHARED VOTING POWER
   
  4,866,132
7 SOLE DISPOSITIVE POWER
   
  0
8 SHARED DISPOSITIVE POWER
   
  4,866,132
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  4,866,132
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)                   ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
  10.5%
12 TYPE OF REPORTING PERSON (See Instructions)
  IN

 

 

 

 

CUSIP NO. 74349U 108    

 

Item 1 (a).Name of Issuer:

 

Prometheus Biosciences, Inc. (the “Issuer”)

 

Item 1 (b).Address of Issuer’s Principal Executive Offices:

 

9410 Carroll Park Drive

San Diego, California 92121

 

Item 2 (a).Name of Person Filing:

 

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

 

Cedars Sinai Intellectual Property Company (“CSIPC”)

Cedars-Sinai Medical Center (“CSMC”)

Thomas M. Priselac

David M. Wrigley

 

Item 2 (b).Address of Principal Business Office or, if None, Residence:

 

The address of the principal business office for each of the Reporting Persons is:

 

c/o Cedars-Sinai Medical Center

8700 Beverly Boulevard

Los Angeles, California 90048

 

Item 2 (c).Citizenship:

 

See cover pages Item 4

 

Item 2 (d).Title of Class of Securities:

 

Common Stock, $0.0001 per value per share (“Common Stock”)

 

Item 2 (e).CUSIP Number:

 

74349U 108

 

Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

Item 4.Ownership

 

The approximate percentages of Common Stock reported as beneficially owned by the Reporting Persons are based upon a statement in a prospectus, dated December 8, 2022, as filed with the Securities and Exchange Commission on December 9, 2022, that there would be 46,393,636 shares of common stock outstanding following the closing, on or about December 13, 2022, of its public offering of shares.

 

The securities reported in this Schedule 13G/A are held directly by CSIPC. CSIPC is a wholly-owned subsidiary of CSMC. CSMC is deemed to share voting and dispositive power with respect to the shares held by CSIPC. Mr. Priselac, the President and Chief Executive Officer of CSMC, and Mr. Wrigley, the Executive Vice President and Chief Financial Officer of CSMC, are deemed to share voting and dispositive power with respect to the shares held by CSIPC. Neither the fact of this filing nor anything contained herein shall be deemed to be an admission by the Reporting Persons that they have formed a group.

 

 

 

 

CUSIP NO. 74349U 108    

 

Item 5.Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person

 

Not applicable.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

 

Not applicable.

 

Item 8.Identification and Classification of Members of the Group

 

Not applicable.

 

Item 9.Notice of Dissolution of Group

 

Not applicable.

 

Item 10.Certifications

 

Not Applicable.

 

 

 

 

CUSIP NO. 74349U 108    

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2023

 

CEDARS SINAI INTELLECTUAL PROPERTY COMPANY, INC.   CEDARS-SINAI MEDICAL CENTER
     
By: /s/ James D. Laur   By: /s/ David M. Wrigley
Name: James D. Laur   Name: David M. Wrigley
Title: Chief Executive Officer   Title: Executive Vice President and Chief Financial Officer
     
David M. Wrigley   THOMAS M. PRISELAC
     
/s/ David M. Wrigley   /s/ Thomas M. Priselac